ISB 2001
Multiple Myeloma
Phase 1bActive
Key Facts
About Ichnos Glenmark Innovation
Ichnos Glenmark Innovation (IGI) is a private, clinical-stage biotech advancing a pipeline of novel multispecific antibodies for oncology, powered by its proprietary BEAT® protein engineering platform. Its lead asset, ISB 2001, is a trispecific T-cell engager in Phase 1b for multiple myeloma, with additional preclinical programs targeting immune modulation. The company is led by an experienced management team with deep oncology drug development expertise and operates from innovation centers in the USA, Switzerland, and India.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |
| Sequesta™ | ID4Pharma | Pre-clinical |